安络化纤丸联合还原型谷胱甘肽治疗非酒精性脂肪性肝病疗效观察

doi:10.3969/j.issn.1672-5069.2014.01.023

Abstract

Liu Chungang, Yuan Yanmei. Reduced glutathione and Anluo Huaqianwan in the treatment of patients with non-alcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 78-79.

[1] 敬晓琴,袁喆. 非酒精性脂肪肝的研究进展. 胃肠病学和肝病学杂志,2008,17（6）：509-512.
[2] 袁平戈. 非酒精性脂肪肝病的诊断和治疗探讨.西部医学,2009,21（2）：333-336.
[3] 刘芳.非酒精性脂肪肝的诊治新进展.中国当代医药,2011,18（21）：20-22.
[4] 王辉,李俊义,曹云峰,等. 安络化纤丸联合辛伐他丁治疗非酒精性脂肪肝30例. 中西医结合肝病杂志,2008,18（1）：58-59.
[5] 谢萍,周新喜,张琴. 非酒精性脂肪肝的发病机制和治疗.中西医结合学报,2010,8（3）：201-209.
[6] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性肝病诊疗指南. 中华内科杂志,2010,49（4）：357.
[7] 余进. 还原型谷胱甘肽在非酒精性脂肪肝患者治疗中的作用.中国医药导报,2011,8（35）：84-85.
[8] 杨永俊,张辉,朱金山. 还原型谷胱甘肽联合安络化纤丸治疗非酒精性脂肪肝疗效分析. 中国当代医药,2010,17（3）：55.
[9] 陈霞.还原型谷胱甘肽联合左卡尼汀对非酒精性脂肪肝患者肝功能和血脂水平的影响.当代医学,2012,18（22）：128-129.
[10] 唐明. 还原型谷胱甘肽联合二甲双胍治疗非酒精性脂肪肝.西部医学,2009,21（5）：784-785.
[11] 张启杰,周平. 还原型谷胱甘肽联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝病的疗效观察. 中国药房,2009,20（17）：1328.
[12] 李晓沛.罗格列酮和还原型谷胱甘肽治疗非酒精性脂肪肝患者疗效观察. 实用肝脏病杂志,2012,15（6）：559-561.
[13] 张海霞. 安络化纤丸治疗非酒精性脂肪肝临床观察.现代诊断与治疗,2012,23（6）：774-775.
[14] 杨红洁,吴穗.安络化纤丸治疗非酒精性脂肪肝临床观察.亚太传统医药,2011,7（6）：78-79.
[15] 王丽华. 安络化纤丸治疗非酒精性脂肪肝临床观察.中国社区医师,2012,14（6）：234.

Reduced glutathione and Anluo Huaqianwan in the treatment of patients with non-alcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[2]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[3]	Fu Liang, Wu Dongbing, Ji Xinzun. Application of ARFI quantification in the evaluation of liver injuries in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 377-380.
[4]	Zhao Xiaoguang, Shi Yujie. Protective effect of reduced glutathione on liver function in patients with advanced primary liver cancer underwent transarterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 425-428.
[5]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[6]	Su Shuting, Zhong Yan, Mi Yuqiang.. Management of patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 293-296.
[7]	Zhang Feng, Yan Yan.. Implication of serum apolipoprotein B levels and its correlation with metabolic syndrome in checked-up individuals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 61-64.
[8]	Song Na, Liu Xiaoyan, Liu Chang, et al.. Changes of plasma thyrotropin levels in patients with nonalcoholic fatty liver disease and type 2 diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 65-68.
[9]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[10]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[11]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[12]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[13]	Xie Zhanfeng, Jia Jizhen, Zhao Shufang. Combination of notoginseng total saponin and silybin in treatment of patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 623-624.
[14]	Yang Yan, Wang Xuan. Diagnosis and treatment of patients with diabetic hepatopathy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 653-656.
[15]	Zhao Wentao, Cao Gaofeng, Jiao Xiaohong, et al. Efficacy of puerarin combined with metformin in the treatment of patients with non-alcoholic fatty liver disease and prediabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 409-412.